Mirae Asset Life Insurance Obtains Exclusive Rights for New Cancer Coverage

Mirae Asset Life Insurance announced on the 11th that it has obtained exclusive usage rights for 3 months and 6 months, respectively, from the Life Insurance Association's Review Committee for two special riders: the 'Non-Hereditary Genetic Testing Coverage Rider with Benefits' and the 'Specific Anticancer Side Effect Treatment Drug Coverage Rider with Benefits.'

By subscribing to the Non-Hereditary Genetic Testing Coverage Rider with Benefits, customers can receive coverage not only for the existing next-generation sequencing (NGS) gene panel tests but also for single-gene tests in next-generation non-hereditary genetic testing, which identifies individual genetic mutations before general chemotherapy to find the optimal treatment method.

The Specific Anticancer Side Effect Treatment Drug Coverage Rider with Benefits guarantees prescription coverage for various side effects occurring during cancer treatment, ranging from relatively mild antiemetics to severe anticancer side effects including neutropenia.

Oh Sang-hoon, Head of Product Development at Mirae Asset Life Insurance, said, “The acquisition of exclusive usage rights for this new cancer coverage is the result of efforts to introduce innovative treatment coverage throughout the entire cancer treatment journey, reflecting consumer needs.” He added, “We hope that Mirae Asset Life Insurance’s groundbreaking cancer coverage will help improve the quality of life for cancer patients.”

This content was produced with the assistance of AI translation services.